StockTipsArenaBeta

BUY Biocon Ltd — Ashish Chaturmohta, JM Financial

BUYBiocon Ltd
Biocon share price target & all analyst calls

byAshish Chaturmohta, JM FinancialHorizon: 1–3 months15 Jul 2026via CNBC Awaaz.

Entry₹410Stated
Target₹550
Total upside +34.15% (call closed)
Stop lossNot given
At expiry₹35215 Oct 2026, 3:30 pm
Expired-14.15%auction close
Follow Ashish Chaturmohta for new calls(27% target hit, 15 closed calls)Get alertsWatch BIOCON for new buy/sell callsGet alertsSee 2 active Short-term calls on BIOCONSee 74 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 15 Oct 2026
30 supporting9 neutral5 opposing
Supports the BUY call (30)

Biocon settles licence agreement with Genetech for cancer treatment drug — Check earliest secured launch dates

NewsCnbc-Tv18·14 Oct · yesterday

(opens in new tab)

Biocon Malaysia arm gets UK regulator approval for Semglee fill finish unit

NewsCnbc-Tv18·25 Sept · 3w ago

(opens in new tab)

Biocon's subsidiary received a positive opinion from EMA's CHMP for its Pertuzumab biosimilar (Pebrilzo) for HER2-positive breast cancer treatment. This is the first biosimilar to receive such recomme

BSE · Company Update·21 Sept · 3w ago

(opens in new tab)

Biocon's biosimilar Pertuzumab has received a positive recommendation from the EMA's CHMP under a new tailored clinical approach, marking a significant regulatory milestone.

NSE · Press Release·21 Sept · 3w ago

(opens in new tab)

1 other SEBI-registered advisor has an active short-term BUY call on this stock

Advisor consensus · same horizon·19 Sept · 4w ago

Neutral / worth noting (9)

Nothing found in this tip’s window yet.

Weighs against the BUY call (5)

1 other SEBI-registered advisor has an active short-term SELL call on this stock, issued in the last 14 days

Advisor consensus · same horizon·9 Oct · 5d ago

US Drug Tariff: 15 Pharma Stocks Likely to Be Impacted by Trump’s New Tariff Plan

NewsGoogle News·16 Sept · 4w ago

(opens in new tab)

2 advisors have active long-term SELL calls on this stock

Advisor consensus · adjacent horizon·15 Jul · 3mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from Ashish Chaturmohta, JM Financial

Every call and its outcome